UBS
US high net worth individuals and business owners are expressing growing intentions to invest as US markets continue to hit record highs in 2019, according to UBS Global Wealth Management's new quarterly Investor Sentiment survey.
The survey, which polled more than 3,800 wealthy investors and entrepreneurs in 17 countries, also shows US investors remain positive on the U.S. stock market but continue to rank politics and the national debt as top concerns. Fifty percent of US investors see a diversified portfolio as a hedge against US-China trade tensions specifically, in line with UBS GWM's own views, compared with 41% who favor cash.
Filippo Ilardi, US Client Strategy Officer at UBS Global Wealth Management , says: "We are pleased to see a substantial increase in investors willing to put more money in the market. Wealthy Americans are concerned about the political environment and US-China trade tensions but we are encouraged that they see diversification as an important way of managing some of these risks."
Overall, 41% of US investor respondents expressed optimism on the global economy and 30% expressed pessimism. This represented an improvement from the 37% who expressed optimism and the 31% who expressed pessimism in the Investor Sentiment survey released in the second quarter.
Thirty-seven percent also expressed an intention to invest more in the markets, up significantly from 26% in the previous quarter. Most investors remain optimistic on US stocks specifically, although the proportion has declined slightly from 57% of respondents to 53%.
US business owners were especially positive, with 81% optimistic about their business compared with 75% in the previous quarter. Overall, 46% said they intended to hire more workers versus 20% in the quarter prior. Business owners' top concern was healthcare costs, as cited by 61% of respondents, up 5 percentage points quarter over quarter. This worry was echoed in part by US high net worth investors, who cited healthcare costs as their third highest concern.
Mike Ryan, Americas Chief Investment Officer at UBS Global Wealth Management, says: "We believe US investors are right to be positive on the US stock market outlook, and we retain an overweight position in US equities in our US client portfolios, although returns for the balance of the year are apt to be more modest given the impressive run for stocks during the first half. We are also likely to see periodic bouts of volatility as investors contend with ongoing trade tension and heightened expectations for Fed rate cuts."
Mark Sanborn, Head of Americas Investment Platforms and Solutions at UBS Global Wealth Management, says: "Wealthy Americans are rightly warming up to US markets amid the ongoing recovery in financial assets in 2019. In addition to interest in US stocks specifically, we are seeing encouraging levels of interest in more diversified portfolios as a means for investors to hedge risk and keep their financial plans on track."
Globally, sentiment also improved in the most recent quarter. The proportion of investors optimistic about the global economy remained unchanged on 51%, while 46% of investors planned to invest more, an increase of 4 percentage points.
After the US, the region with the fastest-growing willingness to invest was the European Union, after the European Central Bank signaled it would consider fresh stimulus in response to the European economic slowdown. Some 47% of European respondents outside Switzerland said they planned to invest more, up 8 percentage points quarter over quarter.
Notes to Editors
About the survey
UBS surveyed 3,899 investors and business owners with at least $1M in investable assets (for investors) or at least $250k in annual revenue and at least one employee other than themselves (for business owners), from June 3 - July 6, 2019. The global sample was split across Brazil, China, Germany, Hong Kong, Indonesia, Italy, Japan, Malaysia, Mexico, Philippines, Singapore, Switzerland, Taiwan, Thailand, the UAE, the UK, and the US.
About UBS Global Wealth Management
As the world's largest wealth manager, UBS Global Wealth Management provides comprehensive advice, solutions and services to wealthy families and individuals around the world. Clients who work with UBS benefit from a fully integrated set of wealth management capabilities and expertise, including wealth planning, investment management, capital markets, banking, lending and institutional and corporate financial advice.
About UBS
UBS provides financial advice and solutions to wealthy, institutional and corporate clients worldwide, as well as private clients in Switzerland. UBS' strategy is centered on our leading global wealth management business and our premier universal bank in Switzerland, enhanced by Asset Management and the Investment Bank. The bank focuses on businesses that have a strong competitive position in their targeted markets, are capital efficient, and have an attractive long-term structural growth or profitability outlook.
UBS is present in all major financial centers worldwide. It has offices in 52 countries, with about 34% of its employees working in the Americas, 34% in Switzerland, 18% in the rest of Europe, the Middle East and Africa and 14% in Asia Pacific. UBS Group AG employs approximately 61,000 people around the world. Its shares are listed on the SIX Swiss Exchange and the New York Stock Exchange (NYSE).
© UBS 2019. All rights reserved. The key symbol and UBS are among the registered and unregistered trademarks of UBS.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190723005638/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Natus Sensory Appoints Arne Boye Nielsen to Board of Directors8.1.2026 08:00:00 CET | Press release
Natus Sensory, a global leader in sensory and diagnostic solutions, today announced the appointment of Arne Boye Nielsen to its Board of Directors, effective January 1, 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260107392331/en/ Arne Boye Nielsen Arne brings more than 30 years of executive leadership experience in diagnostics and medical technology, most notably as President of Demant Diagnostics, where he built and scaled the business into a global leader over three decades. During his tenure, Arne played a central role in shaping Demant Diagnostics’ long-term strategy, portfolio expansion, and international growth, establishing it as a cornerstone of Demant’s global healthcare footprint. In addition to his executive leadership background, Arne brings extensive board experience. His deep expertise across diagnostics, governance, and value creation will further strengthen Natus Sensory’s Board as the company contin
4Moving Biotech Receives FDA IND Clearance for 4P004, Strengthening Its Position as a Leading Innovator in Disease-Modifying Osteoarthritis Therapeutics8.1.2026 07:30:00 CET | Press release
FDA IND clearance enabling the worldwide expansion of the INFLAM MOTION Phase 2a trial, involving major U.S. sites Advancing the first clinical proof of concept in OA with a first-in-class intra-articular GLP-1 agonist A holistic clinical strategy design establishing the foundation for a future accelerated approval pathway 4Moving Biotech (4MB), a clinical stage biotechnology company developing next-generation, disease-modifying therapies for osteoarthritis (OA), today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for 4P004, enabling the expansion of the Phase 2a INFLAM MOTION clinical trial into the United States (US). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260107798042/en/ 4Moving Biotech (4MB), a clinical stage biotechnology company developing next-generation, disease-modifying therapies for osteoarthritis (OA), today announced that the U.S. F
Organon Enters into a Commercialization Agreement for Daiichi Sankyo’s Nilemdo®in France, Denmark, Iceland, Sweden, Finland and Norway8.1.2026 07:30:00 CET | Press release
The agreement builds on Organon’s cardiovascular disease portfolio, leveraging expertise to expand access to new treatments for patients with dyslipidemia, especially statin-intolerant patients.This collaboration addresses a critical gap in care that disproportionately affects women, who are at a 47% higher risk of developing statin intolerance compared to men.i Organon today announced that it has entered into an agreement with Daiichi Sankyo Europe to commercialize Nilemdo® (bempedoic acid) in France, Denmark, Iceland, Sweden, Finland and Norway. Nilemdo® is a new, first-in-class drug indicated for patients with high cholesterol and cardiovascular disease risk. It provides an alternative treatment for patients that cannot be treated effectively with statins.ii “This collaboration combines Organon’s commercial agility with Daiichi Sankyo’s expertise in cardiovascular innovation to bring Nilemdo® to patients in France, Denmark, Iceland, Sweden, Finland and Norway,” says Thibault Crosnie
Prodapt Earns ISO 42001 Certification, the New Global Benchmark for Responsible Enterprise AI8.1.2026 07:00:00 CET | Press release
Prodapt today announced that it has been awarded the ISO 42001 certification, the world’s first and the only global standard for AI Management Systems (AIMS). Marking a significant milestone in its journey, Prodapt is setting a higher benchmark to deliver secure, ethical, and scalable AI for global enterprises. ISO 42001 lays a rigorous framework for governing AI across strategy, technology, and operations. The certification, awarded by an independent accredited body, validates Prodapt’s enterprise-grade AI management framework, including executive-led oversight, strong technology foundations, and disciplined operational processes. These measures ensure AI systems are responsibly designed, deployed, monitored, and evolved throughout their lifecycle. The evaluation emphasizes risk management, ethical AI practices, transparency, and scalability, confirming Prodapt’s ability to proactively identify and mitigate risks while ensuring accountability in AI-driven outcomes. Human-in-the-loop c
Azafaros to Present at J.P. Morgan’s 44th Annual Healthcare Conference8.1.2026 07:00:00 CET | Press release
Azafaros, a company building a portfolio to become a leader in lysosomal storage disorders with the goal of addressing neurological symptoms, today announced that it will present at J.P. Morgan’s 44th Annual Healthcare Conference on Thursday, January 15. The company’s presentation will begin at 9:30 am PT/12:30 am ET/6:30 am CET. The presentation will focus on the company’s lead product, nizubaglustat, a potential treatment for rare lysosomal storage disorders with neurological involvement including GM1/GM2 gangliosidoses and Niemann-Pick type C disease ((NPC). Two pivotal Phase 3 studies investigating nizubaglustat in GM1/GM2 gangliosidoses and NPC are currently enrolling, with data expected in 2027. The studies build on positive data from a robust clinical program including the Phase 2 RAINBOW study and the PRONTO natural history study. The Phase 3 studies are financed following the company’s successful completion of €132 million series B round completed in 1H 2025. About nizubaglust
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom